Cyclic Peptide Compounds for Tissue Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for tissue regeneration, such as using recombinant growth factors, often face challenges like poor stability, slow activity, and potential side effects, limiting their effectiveness in promoting rapid and efficient tissue repair and regeneration.
Innovation Solution
Development of cyclic growth factor receptor-binding compounds that can induce stem cell differentiation and promote tissue regeneration by binding to specific growth factor receptors, enhancing the modulation of gene transcription and cellular differentiation processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant growth factors are used to promote tissue regeneration, then tissue repair capability is improved, but stability and duration of action are insufficient
Solution Approach 1:
The patent introduces cyclic peptide compounds as intermediary molecules that bind to growth factor receptors. These compounds act as mediators between the biocompatible material and the cellular response, providing sustained activation without requiring continuous presence of the original growth factors. The cyclic structure serves as a stable intermediary that maintains biological activity over extended periods.
Solution Approach 2:
The patent modifies the molecular parameters of growth factor interaction by using cyclic peptide structures with specific amino acid sequences. These structural parameter changes enhance stability while maintaining receptor binding affinity. The cyclic conformation protects against proteolytic degradation and extends half-life, directly addressing the duration limitation of conventional recombinant growth factors.
2Reliability
If recombinant growth factors are used to induce stem cell differentiation, then tissue regeneration is promoted, but the process occurs slowly
Solution Approach 1:
The patent creates a dynamic system where cyclic peptide compounds are integrated into biocompatible materials, allowing sustained release and continuous stimulation of stem cell differentiation. This dynamic arrangement maintains optimal concentrations at the tissue interface over time, accelerating the regeneration process compared to single-dose recombinant growth factor administration.
Solution Approach 2:
The cyclic peptide compounds are pre-loaded onto or into the biocompatible material before implantation. This preliminary preparation ensures immediate availability upon implantation, eliminating the delay associated with administering recombinant growth factors after tissue injury occurs. The pre-positioned compounds begin acting on stem cells from the moment of implantation.
3Reliability
If recombinant growth factors are used for tissue repair, then regenerative capability is enhanced, but side effects occur
Solution Approach 1:
The patent implements local delivery of regenerative activity through cyclic peptide compounds embedded in the biocompatible material at the specific tissue defect site. This localized approach concentrates the regenerative effect where needed while minimizing systemic exposure that could cause side effects. The cyclic peptides act locally on nearby stem cells without requiring systemic circulation of recombinant growth factors.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds facilitate faster and more effective tissue regeneration by enhancing stem cell commitment and differentiation, improving the speed and efficacy of tissue repair compared to conventional methods.
Implementation Method 1
cyclic growth factor receptor-binding compounds that can induce stem cell differentiation by binding to specific growth factor receptors
Data Source
AI summary
The present disclosure provides a cyclic peptide, or a variant or analog thereof, or a cyclic peptidomimetic, with between 10 and 35 amino acids, having a growth factor receptor-binding capability and comprising a peptide with four amino acids PEP1; wherein PEP1 is selected from the group consisting of SAIS, SSLS, NAIS, SATS, SPIS, EPIS, SPIN, KPLS, EPLP, EPLT, SNIT, RSVK and RPVQ.